Slides
Page 1
Securities Code : 4521 Supplementary Financial Information Consolidated Financial Results for the Three Months Period June 30 , 2026 ( Under Japanese GAAP ) KAKEN August 7 , 2026 KAKEN PHARMACEUTICAL CO . , LTD .
Page 2
1. Summary of Consolidated Financial Statements for the Three Mo nths Period June 30, 2026 p.2 2. Consolidated Net Sales by Segment p.2 3. Consolidated Overseas Sales p.3 4. Consolidated Capital Expenditures, Depreciation and Amortization p.3 5. Summary of Consolidated Balance Sheet p.4 6. Summary of Non-consolidated Financial Statements for the Thre e Months Period June 30, 2026 p.5 7. Non-consolidated Net Sales by Segment p.5 8. Non-consolidated Overseas Sales p.6 9. Non-consolidated Capital Expen ditures, Depreciation and Amortization p.6 10. Sales of Major Domestic Pharmaceuticals and Medical Devices (Non-consolidated) p.7 11. Pipelines p.8 12. Status of Out-Licensed Products Overseas p.9 Cautionary notes regarding forward-looking statement ・This information contains forward-looking statements on the Kaken groupʼs business. ・ They are projections based on information available at the time this information was prepared, and may differ from actual results due to a variety of factors. ・ In ad dition, although this information includes information related to pharmaceutical products and medical devices (includ ing those under development), these statements are not intended to be advertisement or medical advice. Table of Contents 1
Page 3
1．Summary of Consolidated Financial Statements for the Three Months Period June 30, 2026 (amounts are rounded down to the nearest million Yen) Net sales 18,867 76,871 30,154 11,286 59.8% 89,900 13,028 16.9% Cost of sales 8,995 36,879 9,183 188 2.1% ー ー ー Gross profit 9,872 39,991 20,970 11,097 112.4% ー ー ー Gross Profit Margin 52.3% 52.0% 69.5% ー Selling, general and administrative expenses 9,858 40,891 10,067 209 2.1% 45,900 5,008 12.2% R&D expenses 5,382 20,585 4,599 △ 783 △14.6% 23,900 3,314 16.1% Operating profit 14 △ 899 10,902 10,888 ー 7,900 8,799 ー Operating Profit Margin 0.1% ー 36.2% 8.8% Ordinary profit 417 △ 206 11,258 10,840 ー 8,600 8,806 ー Ordinary Profit Margin 2.2% ー 37.3% 9.6% Profit before income taxes 409 2,313 11,242 10,833 ー ー ー ー Profit 271 2,144 8,439 8,168 ー 6,500 4,355 203.1% Net Profit Margin 1.4% 2.8% 28.0% 7.2% Per share profit (Yen) 7.13 56.57 222.86 171.65 2．Consolidated Net Sales by Segment (amounts are rounded down to the nearest million Yen) Pharmaceuticals 18,229 74,328 29,496 11,266 61.8% 87,300 12,971 17.5% Pharmaceuticals & medical devices 17,070 67,844 27,796 10,725 62.8% 80,700 12,855 18.9% Crop protection 1,108 6,274 1,644 535 48.3% 6,400 125 2.0% Others 50 209 55 5 10.0% 200 △ 9 △4.3% Real estate 638 2,543 657 19 3.1% 2,600 56 2.2% Total 18,867 76,871 30,154 11,286 59.8% 89,900 13,028 16.9% YoY Change (yen) YoY Change (%) YoY Change (yen) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 YoY Change (%) YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 2
Page 4
3．Consolidated Overseas Sales (amounts are rounded down to the nearest million Yen) Pharmaceuticals 1,462 10,303 13,999 12,536 857.3% 27,800 17,496 169.8% Aadi ー 4,348 1,480 1,480 ー 5,200 851 19.6% Crop protection 275 2,536 492 216 78.6% 2,700 163 6.4% Total overseas sales 1,738 12,840 14,491 12,753 733.7% 30,500 17,659 137.5% Overseas Sales Ratio 9.2% 16.7% 48.1% 33.9% *Nine-months performance for Aadi is consolidated in the FY2025. *Aadi’s sales are presented after intercompany eliminations. 4．Consolidated Capital Expenditures, Depreciation and Amortization (amounts are rounded down to the nearest million Yen) Capital expenditures 1,417 3,684 575 △ 841 △59.4% 2,100 △ 1,584 △43.0% Depreciation and amortization 618 3,057 920 302 49.0% 3,700 642 21.0% YoY Change (%) YoY Change (yen) YoY Change (%) YoY Change (yen) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 FY2026 1Q Plan FY2026 YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) FY2025 1Q FY2025 3
Page 5
5．Summary of Consolidated Balance Sheet (amounts are rounded down to the nearest million Yen) As of Mar. 31, As of Jun. 30, 2026 2026 Total assets 178,217 187,414 9,196 Current assets 94,051 103,057 9,005 Cash and Cash Equivalents 50,705 58,143 7,437 Notes and accounts receivable-trade, etc. 19,378 20,357 979 Inventories 19,117 19,372 254 Non-current assets 84,166 84,357 190 Property, plant and equipment 27,134 27,068 △ 66 Intangible assets 24,291 24,375 84 (Goodwill) 5,399 5,419 19 (Marketing Rights) 12,201 12,245 44 (In-process research and development) 5,495 5,519 23 Investments and other assets 32,740 32,913 172 Total liabilities 30,597 34,531 3,933 Current liabilities 20,803 24,628 3,825 Notes and Accounts Payable, etc. 7,566 7,758 191 Short-term Borrowings 3,850 3,850 0 Non-current liabilities 9,794 9,902 107 Total net assets 147,619 152,883 5,263 Common stock 23,853 23,853 0 Capital surplus 11,406 11,406 0 Retained earnings 125,625 130,448 4,822 Treasury stock △ 23,776 △ 23,776 0 YoY Change (yen) 4
Page 6
6．Summary of Non-consolidated Financial Statements for the Three Months Period June 30, 2026 (amounts are rounded down to the nearest million Yen) Net sales 18,817 72,313 28,618 9,801 52.1% 84,400 12,086 16.7% Cost of sales 9,012 36,489 9,074 62 0.7% ー ー ー Gross profit 9,804 35,824 19,543 9,739 99.3% ー ー ー Gross Profit Margin 52.1% 49.5% 68.3% ー Selling, general and administrative expenses 9,770 36,519 8,824 △ 946 △9.7% 39,900 3,380 9.3% R&D expenses 5,382 19,139 4,188 △ 1,193 △22.2% 21,200 2,060 10.8% Operating profit 33 △ 694 10,719 10,685 ー 8,900 9,594 ー Operating Profit Margin 0.2% ー 37.5% 10.5% Ordinary profit 437 △ 112 11,031 10,594 ー 9,500 9,612 ー Ordinary Profit Margin 2.3% ー 38.5% 11.3% Profit before income taxes 428 2,307 11,016 10,587 ー ー ー ー Profit 293 1,965 8,183 7,890 ー 7,400 5,434 276.5% Net Profit Margin 1.6% 2.7% 28.6% 8.8% Per share profit (Yen) 7.71 51.85 216.11 195.41 7．Non-consolidated Net Sales by Segment (amounts are rounded down to the nearest million Yen) Pharmaceuticals & medical devices 17,070 63,495 26,315 9,245 54.2% 75,400 11,904 18.7% Crop protection 1,108 6,274 1,644 535 48.3% 6,400 125 2.0% Real estate 638 2,543 657 19 3.1% 2,600 56 2.2% Total 18,817 72,313 28,618 9,801 52.1% 84,400 12,086 16.7% YoY Change (%) YoY Change (yen) YoY Change (%) Plan FY2026 YoY Change (yen) FY2025 1Q FY2025 FY2026 1Q YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 5
Page 7
8．Non-consolidated Overseas Sales (amounts are rounded down to the nearest million Yen) Pharmaceuticals 1,431 5,831 12,503 11,072 773.7% 22,600 16,768 287.5% Crop protection 275 2,536 492 216 78.6% 2,700 163 6.4% Total overseas sales 1,706 8,368 12,996 11,289 661.4% 25,300 16,931 202.3% Overseas Sales Ratio 9.1% 11.6% 45.4% 30.0% 9．Non-consolidated Capital Expenditures, Depreciation and Amortization (amounts are rounded down to the nearest million Yen) Capital expenditures 1,416 3,520 502 △914 △64.6% 2,100 △ 1,420 △40.3% Depreciation and amortization 618 2,614 779 161 26.1% 3,200 585 22.4% YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 FY2025 1Q FY2025 FY2026 1Q Plan FY2026 6
Page 8
10．Sales of Major Domestic Pharmaceuticals and Medical Devices (Non-consolidated) (amounts are rounded down to the nearest million Yen) Clenafin group 4,377 13,245 2,310 △ 2,066 △47.2% 7,900 △5,345 △40.4% Clenafin 4,377 9,079 393 △ 3,983 △91.0% ーー ー 【AG】 Efinaconazole「KAKEN」 ー 4,165 1,916 ー ー ーー ー Artz 4,614 18,469 4,508 △ 106 △2.3% 17,700 △769 △4.2% Seprafilm 1,729 7,002 1,721 △ 7 △0.5% 7,000 △2 △0.0% Ecclock 803 2,318 832 29 3.6% 2,600 281 12.2% Fiblast 565 2,287 517 △ 48 △8.5% 2,100 △187 △8.2% Regroth 220 865 222 1 0.8% 900 34 4.0% Hernicore 78 288 89 10 13.0% 400 111 38.9% Generic products (total) （excluding AG） 1,824 7,396 1,796 △ 28 △1.6% 7,100 △296 △4.0% YoY Change (yen) YoY Change (%) YoY Change (yen) YoY Change (%) FY2025 1Q FY2025 FY2026 1Q Plan FY2026 Onychomycosis treatment Anti-osteoarthritis agent Post-operative anti-adhesive Wound-healing agent Periodontal regenerative agent Primary axillary hyperhidrosis treatment Lumbar disc herniation treatment 7
Page 9
11．Pipelines As of August 7, 2026 ＜In-house and in-licensed projects＞ *Bold: changes from previous disclosure. Development code Planned Indication Development Stage * In-house/In-licensed Remarks KAR Head lice Authorization application Arbor Pharmaceuticals, LLC (Currently, Azurity Pharmaceuticals) ・Filed a Marketin g Authorization in June 2026 ・Presented PIII trial results at the 125th Annual Meeting of the Japanese Dermatological Association ・Produ ct name in the US: Sklice® KP-001 Refractory vascular malformations Authorization application in-house ・Filed a Marketing Authorization in May 2026 ・Presented PIII trial results at the 22nd Annual Meeting of the Japanese Society for the Study of Vascular Anomalies ・Th e long-term trial is ongoing ・Generic Name︓serabelisib KC-8025 Primary biliary cholangitis PIII CymaBay Therapeutics, Inc. (Currently, Gilead Sciences, Inc.) ・Product name in US, UK︓Livdelzi ® ・Product name in EU, CA : Lyvdelzi® ・Generic Name︓seladelpar Plaque psoriasis PIII ・Announced the top line data from global PIII trial (incl. Japan) ・The long-term trial is ongoing ・Generic Name︓envudeucitinib ・Generalized pustular psoriasis ・Erythrodermic psoriasis PIII Generic Name︓envudeucitinib Navenibart Hereditary angioedema PIII Astria Therapeutics, Inc. （Currently, BioCr yst Pharmaceuticals, Inc.） Under global PIII trial (incl. Japan) KP-483 Solid tumors (Immuno-oncology) PI in-house Presented PI trial results at ASCO 2026 KP-910 Peripheral neuropathic pain PI in-house ー KP-001 (US) Refractory vascular malformations PIII in-house ・Clin ical trial countries:US, CA, Taiwan, Korea ・ Generic Name︓serabelisib *The development stage includes the preparatory period for clinical trials. *In-house is defined as pipelines acquired prior to obtaining POC and the company holds development rights. Note: Kaken will advance KP-723, an oral STAT6 inhibitor, to the completion of PI trial, which had entered into a license agreement with J&J. ESK-001 Alumis Inc. 8
Page 10
11．Pipelines As of August 7, 2026 ＜Partnered pipeline products＞ *Bold: changes from previous disclosure. Development code Planned Indication Development Stage * gMSC1 Knee osteoarthritis with focal defect Preparing for PIII NM26 Atopic dermatitis PII Note: The medical device “Silk-Elastin Wound Healing Sheet” for the treatment of wounds, including refractory wounds, is under preparation for its launch. 12．Status of Out-Licensed Products Overseas As of August 7, 2026 *Bold: changes from previous disclosure. Generic name (Japanese Product Name) Planned indication Development Stage Out-licensed Developing country Efinaconazole (Clenafin) Onychomycosis Authorization application AIM China Note: Efinaconazole (overseas product name: Jublia), which was out-licensed to Almirall, was launched in Germany in May 2026. Remarks ・A llogenic synovial mesenchymal stem cell-derived three-dimensional artificial tissue ・D eveloped by the licensor, TWOCELLS Co., Ltd. ・ Joint development and exclusive sales rights in the area of orthopedics in Japan ・ Clinical trial underway by J&J after IP transfer ・Opt ional rights to negotiate a sales partnership agreement in Japan ・PIIb t rial discontinued, as announced by J&J (December 26, 2025) 9